Want to see SEPN full AI Analyst Report?
SEPN Stock Chart & Stats
$33.10
$0.14(0.42%)
At close: 4:00 PM EDT
$33.10
$0.14(0.42%)
Day’s Range― - ―
52-Week Range$11.70 - $51.10
Previous CloseN/A
Volume33.99K
Average Volume (3M)489.97K
Market Cap
$1.89B
Enterprise Value$1.16K
Total Cash (Recent Filing)$372.32M
Total Debt (Recent Filing)$22.55M
Price to Earnings (P/E)―
Beta2.12
Next Earnings
Nov 25, 2026EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding46,676,950
10 Day Avg. Volume335,874
30 Day Avg. Volume489,971
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)3.23
Price to Sales (P/S)26.85
P/FCF Ratio11.25
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$52.88Price Target Upside59.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.32
Revenue Forecast (FY)$97.64M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue ScalingRapid revenue expansion indicates meaningful commercial or partnership momentum and provides a stronger base for funding Septerna’s GPCR pipeline. If sustained, scale can improve operating leverage and support broader clinical development.
Strong Cash GenerationPositive operating and free cash flow strengthens internal funding capacity for research and development, reducing near-term reliance on external capital. The improvement from earlier periods suggests a materially stronger funding position.
Conservative Balance SheetLow leverage limits financial risk and preserves flexibility while Septerna advances its pipeline. Substantial equity and assets provide support for ongoing R&D, clinical programs and potential commercialization investments.
Bears Say
Persistent Net LossesSepterna remains unprofitable, showing that revenue growth has not yet covered operating and development costs. Continued losses could require sustained financing or depend on further revenue growth before durable earnings emerge.
Cash Flow Durability RiskRecent cash generation is a major strength, but its slight decline and improvement from previously negative periods raise questions about repeatability. Ongoing monitoring is needed to confirm that inflows support durable operating funding.
Clinical Execution DependenceThe company’s long-term value depends on translating GPCR discovery into clinical evidence and approvals. Clinical development carries execution, regulatory and pipeline-concentration risks that can delay revenue and profitability.
Septerna, Inc. News
SEPN FAQ
What was Septerna, Inc.’s price range in the past 12 months?
Septerna, Inc. lowest stock price was $11.70 and its highest was $51.10 in the past 12 months.
What is Septerna, Inc.’s market cap?
Septerna, Inc.’s market cap is $1.89B.
When is Septerna, Inc.’s upcoming earnings report date?
Septerna, Inc.’s upcoming earnings report date is Nov 25, 2026 which is in 91 days.
How were Septerna, Inc.’s earnings last quarter?
Septerna, Inc. released its earnings results on Aug 10, 2026. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.426 by $0.136.
Is Septerna, Inc. overvalued?
According to Wall Street analysts Septerna, Inc.’s price is currently Undervalued.
Does Septerna, Inc. pay dividends?
Septerna, Inc. does not currently pay dividends.
What is Septerna, Inc.’s EPS estimate?
Septerna, Inc.’s EPS estimate is -0.42.
How many shares outstanding does Septerna, Inc. have?
Septerna, Inc. has 46,676,950 shares outstanding.
What happened to Septerna, Inc.’s price movement after its last earnings report?
Septerna, Inc. reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.426. Following the earnings report the stock price went up 22.934%.
Which hedge fund is a major shareholder of Septerna, Inc.?
Currently, no hedge funds are holding shares in SEPN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Septerna, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.88 (59.74% Upside)
$52.88 (59.74% Upside)
Blogger Sentiment
Neutral
SEPN Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 286.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $63.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.3%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
141.28%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
36.49%
Trailing 12-Months
Company Description
Septerna, Inc.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
SEPN Stock 12 Month Forecast
Average Price Target
$52.88
▲(59.74% Upside)
Technical Analysis
Theravance Biopharma
―
Kura Oncology
―
Gossamer Bio
―
Maravai Lifesciences Holdings
―
―
Ownership Overview
6.12% Insiders
8.46% Mutual Funds
28.12% Other Institutional Investors
50.41% Public Companies and
Individual Investors